Study guide
7.4 Dosage Adjustments in Renal and Hepatic Impairment
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
7.4 Dosage Adjustments in Renal and Hepatic Impairment
Key Takeaways Explain This Topic AI
In renal impairment, loading doses depend on Volume of Distribution (Vd) and remain unchanged, whereas maintenance doses must be reduced or dosing intervals extended proportionally to the decline in clearance.
The Cockcroft-Gault equation is the regulatory standard for drug dosing adjustments; adjusted body weight must be used in obese individuals to prevent overestimating creatinine clearance.
The 'Triple Whammy' drug combination (ACEi/ARB + NSAID + Diuretic) triggers severe acute kidney injury by simultaneously reducing renal perfusion, blocking afferent arteriolar vasodilation, and inducing efferent arteriolar vasodilation.
In hepatic cirrhosis, portosystemic shunting causes a dramatic surge in the bioavailability of high-extraction-ratio drugs (e.g., morphine, propranolol, verapamil), requiring substantial oral dose reductions.
Child-Pugh scoring stratifies hepatic impairment (Classes A, B, C); NSAIDs are strictly contraindicated in cirrhosis due to variceal hemorrhage, platelet inhibition, and precipitation of hepatorenal syndrome.
Last updated: August 2026
Renal Impairment: Assessment and Dosing Principles
The kidneys represent the primary organ for the elimination of hydrophilic parent drugs and polar metabolites. Declines in glomerular filtration rate (GFR), tubular secretion, and tubular reabsorption alter drug clearance, prolonged elimination half-lives, and generate systemic drug accumulation.
Renal Function Estimation: Cockcroft-Gault Equation
Although nephrologists use the CKD-EPI equation (indexed to 1.73 m 2 1.73\text{ m}^2 1.73 m 2 BSA) for staging chronic kidney disease, Health Canada and FDA drug monographs and manufacturer dosing guidelines are standardized to non-indexed Creatinine Clearance (CrCl in mL/min) calculated via the Cockcroft-Gault equation . CrCl (mL/min) = ( 140 − Age [years] ) × Weight [kg] 72 × Serum Creatinine [mg/dL] × ( 0.85 if female ) \text{CrCl (mL/min)} = \frac{(140 - \text{Age [years]}) \times \text{Weight [kg]}}{72 \times \text{Serum Creatinine [mg/dL]}} \times (0.85\text{ if female}) CrCl (mL/min) = 72 × Serum Creatinine [mg/dL] ( 140 − Age [years] ) × Weight [kg] × ( 0.85 if female )
When Serum Creatinine is reported in SI units ( μ mol/L \mu\text{mol/L} μ mol/L ): CrCl (mL/min) = ( 140 − Age [years] ) × Weight [kg] × 1.2 Serum Creatinine [ μ mol/L] × ( 0.85 if female ) \text{CrCl (mL/min)} = \frac{(140 - \text{Age [years]}) \times \text{Weight [kg]} \times 1.2}{\text{Serum Creatinine [}\mu\text{mol/L]}} \times (0.85\text{ if female}) CrCl (mL/min) = Serum Creatinine [ μ mol/L] ( 140 − Age [years] ) × Weight [kg] × 1.2 × ( 0.85 if female )
Body Weight Selection Rules for Cockcroft-Gault
Underweight ( Actual Body Weight [ABW] < Ideal Body Weight [IBW] \text{Actual Body Weight [ABW]} < \text{Ideal Body Weight [IBW]} Actual Body Weight [ABW] < Ideal Body Weight [IBW] ): Use Actual Body Weight (ABW) .
Normal Weight ( ABW within 100 − 120 % of IBW \text{ABW within } 100-120\% \text{ of IBW} ABW within 100 − 120% of IBW ): Use IBW (or ABW depending on institutional policy).
Obese ( ABW > 120 % of IBW \text{ABW} > 120\% \text{ of IBW} ABW > 120% of IBW ): Use Adjusted Body Weight ( A adj A_{\text{adj}} A adj ) to avoid drastically overestimating CrCl due to excess metabolically inactive adipose mass: A adj = IBW + 0.4 × ( ABW − IBW ) A_{\text{adj}} = \text{IBW} + 0.4 \times (\text{ABW} - \text{IBW}) A adj = IBW + 0.4 × ( ABW − IBW )
Ideal Body Weight (Devine Formula):
IBW Male = 50 kg + 2.3 kg × ( Height in inches − 60 ) \text{IBW}_{\text{Male}} = 50\text{ kg} + 2.3\text{ kg} \times (\text{Height in inches} - 60) IBW Male = 50 kg + 2.3 kg × ( Height in inches − 60 )
IBW Female = 45.5 kg + 2.3 kg × ( Height in inches − 60 ) \text{IBW}_{\text{Female}} = 45.5\text{ kg} + 2.3\text{ kg} \times (\text{Height in inches} - 60) IBW Female = 45.5 kg + 2.3 kg × ( Height in inches − 60 )
Pharmacokinetic Dosage Adjustment Strategies in Renal Disease +-------------------------------------------------------------------------+
- | RENAL DOSAGE ADJUSTMENT STRATEGIES |
- +-------------------------------------------------------------------------+
- | 1. LOADING DOSE PRINCIPLE: |
- | - Loading Dose = Target Concentration x Volume of Distribution |
- | - UNCHANGED in renal impairment! (Clearance does NOT affect Vd) |
- | |
- | 2. MAINTENANCE DOSE STRATEGIES: |
- | - Maintenance Dose Rate = Target Steady-State Conc. x Clearance |
- | |
- | A. DOSE REDUCTION METHOD: |
- | * Administer lower dose at standard dosing interval |
- | * Keeps constant steady-state with small peak-trough swings |
- | * Preferred for TIME-DEPENDENT antibiotics (e.g., beta-lactams) |
- | |
- | B. INTERVAL EXTENSION METHOD: |
- | * Administer standard full dose at longer time intervals |
- | * Preserves high peak-to-MIC ratios |
- | * Preferred for CONCENTRATION-DEPENDENT drugs (aminoglycosides) |
- | |
- | C. COMBINED METHOD: |
- | * Decrease dose AND extend interval (e.g., Vancomycin, LMWH) |
- +-------------------------------------------------------------------------+
- High-Risk Renally Eliminated Medications
Drug Class / Drug Clearance Mechanism & Threshold Clinical Hazard if Unadjusted
Metformin 100 % 100\% 100% renal tubular excretion; hold if eGFR < 30 mL/min / 1.73 m 2 \text{eGFR} < 30\text{ mL/min}/1.73\text{ m}^2 eGFR < 30 mL/min /1.73 m 2 ; max 1000 mg 1000\text{ mg} 1000 mg if 30 − 44 mL/min 30-44\text{ mL/min} 30 − 44 mL/min Accumulates in mitochondria → \rightarrow → blocks gluconeogenesis → \rightarrow → severe Lactic Acidosis (50% mortality)
Dabigatran 80 % 80\% 80% renal excretion; avoid if CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min Massive accumulation → \rightarrow → catastrophic gastrointestinal and intracranial hemorrhage
Enoxaparin (LMWH) Renal elimination; reduce to once daily if CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min Anti-Xa accumulation → \rightarrow → severe retroperitoneal and surgical site bleeding
Morphine & Codeine Active polar metabolites (Morphine-6-glucuronide [M6G], Morphine-3-glucuronide [M3G]) accumulate M6G causes severe respiratory depression/coma; M3G causes neurotoxicity, myoclonus, hyperalgesia. Preferred in CKD: Fentanyl, Methadone
Gabapentin & Pregabalin 100 % 100\% 100% unchanged renal excretion; reduce dose by up to 80 % 80\% 80% in severe CKD Severe somnolence, confusion, myoclonus, ataxia, respiratory depression
Nitrofurantoin Requires adequate tubular filtration for urinary efficacy; avoid if CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min Subtherapeutic urinary levels → \rightarrow → treatment failure; systemic accumulation → \rightarrow → peripheral neuropathy, pulmonary fibrosis
The "Triple Whammy" Acute Kidney Injury Mechanism
Concurrent use of an ACE inhibitor or ARB , an NSAID , and a Diuretic creates a catastrophic hemodynamic collapse of intraglomerular hydrostatic pressure:
Diuretic: Depletes intravascular volume and reduces renal blood flow.
NSAID: Inhibits cyclooxygenase (COX-1/2), blocking synthesis of vasodilatory prostaglandins ( P G E 2 , P G I 2 PGE_2, PGI_2 PG E 2 , PG I 2 ) at the afferent arteriole → \rightarrow → severe afferent arteriolar vasoconstriction.
ACE inhibitor / ARB: Blocks angiotensin II-mediated vasoconstriction at the efferent arteriole → \rightarrow → efferent arteriolar vasodilation.
Result: Afferent inflow is choked while efferent outflow remains wide open → \rightarrow → collapse of glomerular filtration pressure → \rightarrow → precipitous prerenal Acute Kidney Injury (AKI) and life-threatening hyperkalemia.
Dialysis Clearance Principles (Hemodialysis vs Peritoneal Dialysis)
Factors governing whether a medication is removed by hemodialysis:
Molecular Weight: Small molecules ( < 500 Da < 500\text{ Da} < 500 Da ) cross dialyzer pores easily. Large macromolecules ( > 1000 − 2000 Da > 1000-2000\text{ Da} > 1000 − 2000 Da ) are not cleared by standard low-flux filters.
Plasma Protein Binding: Only unbound (free) drug traverses the dialysis membrane. Drugs with high protein binding ( > 80 − 90 % > 80-90\% > 80 − 90% , e.g., warfarin, ceftriaxone, phenytoin) are poorly dialyzed.
Volume of Distribution ( V d V_d V d ): Drugs with large V d V_d V d ( > 1 − 2 L/kg > 1-2\text{ L/kg} > 1 − 2 L/kg , e.g., digoxin, TCAs, amiodarone) reside predominantly in peripheral tissue compartments and are not effectively cleared by hemodialysis. Drugs with small V d V_d V d ( < 0.5 L/kg < 0.5\text{ L/kg} < 0.5 L/kg , e.g., aminoglycosides, beta-lactams) are substantially dialyzed.
Water Solubility: Hydrophilic drugs dialyze readily; highly lipophilic drugs do not.
Clinical Rule: Administer dialyzable medications (e.g., ampicillin, cefazolin, aminoglycosides, gabapentin ) after the hemodialysis session (or give a post-dialysis supplemental replacement dose) to prevent therapeutic failure.
- Hepatic Impairment and Cirrhosis Pharmacokinetics
- Child-Pugh Staging System
The Child-Pugh score grades the severity of chronic liver disease using 5 clinical and laboratory parameters: +-------------------------------------------------------------------------+
- | CHILD-PUGH CLASSIFICATION |
- +-------------------------------------------------------------------------+
- | PARAMETERS ASSESSED (1 to 3 points each): |
- | 1. Total Bilirubin (< 34 umol/L = 1; 34-50 = 2; > 50 = 3) |
- | 2. Serum Albumin (> 35 g/L = 1; 28-35 = 2; < 28 = 3) |
- | 3. INR (< 1.7 = 1; 1.7-2.2 = 2; > 2.2 = 3) |
- | 4. Ascites (None = 1; Mild/Controlled = 2; Moderate/Severe = 3) |
- | 5. Hepatic Encephalopathy (None = 1; Grade I-II = 2; Grade III-IV = 3) |
- | |
- | SEVERITY STAGING: |
- | - Class A (5 to 6 points): Mild impairment (100% 1-year survival) |
- | - Class B (7 to 9 points): Moderate impairment (80% 1-year survival; |
- | typically requires 25-50% dose reduction for hepatically cleared drug|
- | - Class C (10 to 15 points): Severe impairment (45% 1-year survival; |
- | avoid hepatically cleared drugs with narrow therapeutic index) |
- +-------------------------------------------------------------------------+
- High vs. Low Extraction Ratio Drugs in Cirrhosis
High Extraction Ratio Drugs ( E H > 0.7 E_H > 0.7 E H > 0.7 , Flow-Limited Clearance):
Examples: Morphine, Propranolol, Metoprolol, Verapamil, Lidocaine, Labetalol .
In healthy livers, these drugs undergo extensive first-pass metabolism ( 60 − 90 % 60-90\% 60 − 90% extraction). In cirrhosis, fibrous tissue architecture and portosystemic shunting divert portal blood directly into systemic circulation, bypassing hepatocytes.
Clinical Impact: Oral bioavailability surges by 200 % to 400 % 200\%\text{ to }400\% 200% to 400% , causing massive, potentially toxic systemic exposure at standard oral doses. Oral doses must be reduced by 50 − 75 % 50-75\% 50 − 75% .
Low Extraction Ratio Drugs ( E H < 0.3 E_H < 0.3 E H < 0.3 , Capacity-Limited / Enzyme-Limited Clearance):
Examples: Warfarin, Phenytoin, Theophylline, Diazepam, Valproic Acid .
Clearance is independent of blood flow but strictly dependent on intrinsic CYP450 enzyme capacity ( C L int CL_{\text{int}} C L int ) and unbound fraction ( f u f_u f u ). Cirrhosis destroys functional hepatocytes, reducing enzyme synthesis and albumin production, prolonging half-lives.
Critical Medication Safety in Cirrhosis
Acetaminophen: Contrary to widespread myth, acetaminophen is the safest first-line analgesic in cirrhosis when used at a reduced maximum dose of ≤ 2000 mg/day \le 2000\text{ mg/day} ≤ 2000 mg/day in divided doses ( 500 mg 500\text{ mg} 500 mg PO QID or 650 mg 650\text{ mg} 650 mg PO TID). It lacks renal, vascular, and gastrointestinal toxicity.
NSAIDs: Strictly contraindicated in cirrhosis and portal hypertension . NSAIDs inhibit renal prostaglandins, precipitating Hepatorenal Syndrome (rapidly fatal functional renal failure), trigger catastrophic gastrointestinal bleeding from esophageal/gastric varices, and exacerbate portal hypertension-induced ascites through profound sodium retention.
Sedatives and Opioids: Benzodiazepines, opioids, and z-drugs can precipitate or exacerbate Hepatic Encephalopathy due to impaired drug clearance and heightened baseline neuro-GABAergic sensitivity.
Which constant does the exam expect? The PEBC reference sheet supplied on screen during the Evaluating Examination gives the male form as (140 minus age) x actual body weight (kg) x 1.2 divided by serum creatinine in micromol/L, with the female value obtained by multiplying the male result by 0.85 (an effective factor of about 1.02). Many textbooks print 1.23 and 1.04 instead; the two forms differ by under 3% and rarely change a dosing band, but answer with the sheet you are given.